tysabri
biogen netherlands b.v. - natalizumab - stwardnienie rozsiane - selektywne leki immunosupresyjne - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
bendamustyna medac 2,5 mg/ml proszek do sporządzania koncentratu roztworu do infuzji
medac gesellschaft für klinische spezialpräparate mbh - bendamustini hydrochloridum monohydricum - proszek do sporządzania koncentratu roztworu do infuzji - 2,5 mg/ml
linezolid eugia 2 mg/ml roztwór do infuzji
eugia pharma (malta) ltd. - linezolidum - roztwór do infuzji - 2 mg/ml
clofarabine norameda 1 mg/ml koncentrat do sporządzania roztworu do infuzji
uab norameda - clofarabine - koncentrat do sporządzania roztworu do infuzji - 1 mg/ml
darunavir aurovitas 600 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - darunavirum - tabletki powlekane - 600 mg
clopidogrel aurovitas 75 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - clopidogrelum hydrosulfas - tabletki powlekane - 75 mg
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
symazide mr 30 30 mg tabletki o zmodyfikowanym uwalnianiu
symphar sp. z o.o. - gliclazidum - tabletki o zmodyfikowanym uwalnianiu - 30 mg
zofran 4 mg tabletki powlekane
sandoz gmbh - ondansetroni hydrochloridum dihydricum - tabletki powlekane - 4 mg
zofran 8 mg tabletki powlekane
sandoz gmbh - ondansetroni hydrochloridum dihydricum - tabletki powlekane - 8 mg